FDA Approved: ADEMPAS — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)

View source ↗

Summary

FDA approved a supplemental application for ADEMPAS (riociguat) submitted by Bayer HealthCare Pharmaceuticals Inc., resulting in an updated product label.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension
• Thromboembolic Pulmonary Hypertension

Drugs mentioned

• Adempas (riociguat)

Snippet

SUPPL AP for ADEMPAS (RIOCIGUAT)